» Authors » Alexander Tzankov

Alexander Tzankov

Explore the profile of Alexander Tzankov including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 29
Citations 1603
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Bonometti A, Tzankov A, Alborelli I, Russkamp N, Dertinger S, Dirnhofer S
Virchows Arch . 2024 Aug; PMID: 39107523
Intrasinusoidal bone marrow involvement is an infrequent histological pattern observed in a limited number of B and T cell lymphomas. Mantle cell lymphoma is a biologically and prognostically heterogeneous B...
2.
Bonfiglio F, Bruscaggin A, Guidetti F, di Bergamo L, Faderl M, Spina V, et al.
Blood . 2021 Oct; 139(5):732-747. PMID: 34653238
Splenic marginal zone B-cell lymphoma (SMZL) is a heterogeneous clinico-biological entity. The clinical course is variable, multiple genes are mutated with no unifying mechanism, and essential regulatory pathways and surrounding...
3.
Cai Q, Tu M, Xu-Monette Z, Sun R, Manyam G, Xu X, et al.
Mod Pathol . 2017 Mar; 30(6):854-876. PMID: 28281555
Dysregulated NF-κB signaling is critical for lymphomagenesis, however, the expression and clinical relevance of NF-κB subunit p50 in diffuse large B-cell lymphoma have not been evaluated. In this study, we...
4.
Xu-Monette Z, Deng Q, Manyam G, Tzankov A, Li L, Xia Y, et al.
Clin Cancer Res . 2016 Mar; 22(14):3593-605. PMID: 26927665
Purpose: MYC is a critical driver oncogene in many cancers, and its deregulation in the forms of translocation and overexpression has been implicated in lymphomagenesis and progression of diffuse large...
5.
Xu-Monette Z, Dabaja B, Wang X, Tu M, Manyam G, Tzankov A, et al.
Mod Pathol . 2015 Nov; 28(12):1555-73. PMID: 26541272
MYC dysregulation, including MYC gene rearrangement and Myc protein overexpression, is of increasing clinical importance in diffuse large B-cell lymphoma (DLBCL). However, the roles of MYC and the relative importance...
6.
Crescenzo R, Abate F, Lasorsa E, Tabbo F, Gaudiano M, Chiesa N, et al.
Cancer Cell . 2015 Apr; 27(4):516-32. PMID: 25873174
A systematic characterization of the genetic alterations driving ALCLs has not been performed. By integrating massive sequencing strategies, we provide a comprehensive characterization of driver genetic alterations (somatic point mutations,...
7.
Ok C, Li L, Xu-Monette Z, Visco C, Tzankov A, Manyam G, et al.
Clin Cancer Res . 2014 Mar; 20(9):2338-49. PMID: 24583797
Purpose: Epstein-Barr virus-positive (EBV(+)) diffuse large B-cell lymphoma (DLBCL) of the elderly is a variant of DLBCL with worse outcome that occurs most often in East-Asian countries and is uncommon...
8.
Wang S, Tzankov A, Xu-Monette Z, Hoeller S, Wang S, Richards K, et al.
Hum Pathol . 2013 Sep; 44(12):2658-67. PMID: 24071012
Composite lymphoma with follicular lymphoma (FL) and mantle cell lymphoma (MCL) components is rare and can pose a substantial diagnostic challenge. We report two cases of composite lymphoma with FL...
9.
Xu-Monette Z, Moller M, Tzankov A, Montes-Moreno S, Hu W, Manyam G, et al.
Blood . 2013 Aug; 122(15):2630-40. PMID: 23982177
MDM2 is a key negative regulator of the tumor suppressor p53, however, the prognostic significance of MDM2 overexpression in diffuse large B-cell lymphoma (DLBCL) has not been defined convincingly. In...
10.
Nogai H, Wenzel S, Hailfinger S, Grau M, Kaergel E, Seitz V, et al.
Blood . 2013 Jul; 122(13):2242-50. PMID: 23869088
Constitutive activation of the nuclear factor-κ B (NF-κB) pathway is a hallmark of the activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL). Recurrent mutations of NF-κB regulators that...